

Special Issue

Molecular Research of Neurodegenerative and Psychiatric Diseases, 2nd Edition

Message from the Guest Editor

Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington's disease, as well as psychiatric diseases, such as schizophrenia, anxiety, depression and addictions, are multifactorial and heterogeneous disorders, which pose significant health, social and economic problems. The elucidation of their molecular background may contain keys for identifying risk factors, offering novel diagnostic or prognostic biomarkers, as well as providing novel and specific targets for their prevention and treatment. This Special Issue aims to present the most up-to-date findings regarding research targeting molecular mechanisms underlying different neurodegenerative and psychiatric diseases. It aims to provide a broad overview of novel advances in the field, including studies at the molecular, epi/genetic and cellular levels, but will also cover integrative, imaging and psychopharmacology research areas, as well as comprehensive omics approaches. We welcome the submission of studies using various preclinical in vitro and in vivo models, as well as clinical studies involving human subjects.

Guest Editor

Dr. Dubravka Švob Štrac

Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka cesta 54, 10 000 Zagreb, Croatia

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/207246

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).